Articles tagged with Multiple Myeloma
The John Theurer Cancer Center is presenting 16 research abstracts on various areas of oncology during the ASCO Annual Meeting. These studies include Phase I and II trials for multiple myeloma, lymphoma, and cutaneous T-cell lymphoma treatments.
A study of 792 patients with multiple myeloma found that vertebroplasty significantly reduced pain intensity, medication usage, and disability. The procedure improved mobility in nearly half of the patients, who also reported considering vertebroplasty again if needed.
A University of Leeds research project aims to develop new treatments for multiple myeloma patients, using techniques such as injecting cements into the spine. The study seeks to improve quality of life for patients suffering from this incurable bone marrow cancer.
A phase II clinical trial shows that carfilzomib induces a response in 45% of patients with relapsed or resistant multiple myeloma, reducing neuropathy side effects. The drug also demonstrates good tolerability and dose flexibility.
A new three-drug combination has shown a highly effective regimen in treating newly diagnosed patients with multiple myeloma, with partial responses or better seen in all 66 patients. The treatment also resulted in encouraging complete or near-complete responses at 54 percent.
A recent study published in Leukemia suggests that genetic changes in response to environmental toxins may contribute to the development of multiple myeloma. The study found associations between specific DNA sequence variations and an increased risk of bone disease in myeloma patients.
The UK's National Institute for Health and Clinical Excellence (NICE) has approved the use of lenalidomide in patients with multiple myeloma who have received two or more previous therapies. The approval is based on robust data showing that lenalidomide can increase survival by over three months compared to dexamethasone.
A study of 678 pesticide users found a double risk of developing MGUS compared to the general population. The research suggests exposure to certain pesticides increases the risk of this abnormal blood condition, which requires lifelong monitoring as it can lead to multiple myeloma.
A new partnership between UCSF and MMRF aims to accelerate the development of next-generation treatments for multiple myeloma. The initiative will leverage UCSF's expertise in translational research to identify new therapeutic targets and bring them to clinical trials.
A team of researchers developed an antibody targeting FGFR3, which showed potent antitumor activity against human bladder cancer cells and t(4;14)-positive multiple myeloma cells. The antibody also demonstrated activity against normal FGFR3 and mutated forms associated with cancer.
A novel hemodialysis procedure called high cut-off hemodialysis has been shown to restore kidney function and increase lifespan in patients with multiple myeloma, a form of cancer that causes severe kidney failure. In a study of 19 patients who underwent the procedure while receiving chemotherapy, 70% became independent of dialysis.
Phase II trials demonstrate significant activity of pomalidomide in MM and myelofibrosis, with disease improvement or stabilization in 76% of patients. Pomalidomide also shows promise in patients who previously did not respond to REVLIMID therapy.
A landmark analysis found that continuous treatment with Revlimid and dexamethasone improved overall survival and time to disease progression in multiple myeloma patients. Patients who continued therapy had significantly longer overall survival rates compared to those who discontinued treatment after 10 months or less.
The ECOG E4A03 study found that Revlimid plus low-dose dexamethasone improved three-year overall survival rates to 75% in the intent-to-treat population. Continuous therapy also achieved a 91% overall response rate with a high complete response and very good partial response rate.
Early investigational studies show anti-tumor activity in ZOLINZA (vorinostat) and bortezomib combination for relapsed or refractory multiple myeloma. Clinical trials are underway to further evaluate this combination, offering new hope for advanced multiple myeloma patients.
A new combination of medications has improved or stabilized disease in 76% of patients with relapsed multiple myeloma. Pomalidomide combined with dexamethasone showed promising results, with minimal side effects.
Researchers at Johns Hopkins Kimmel Cancer Center found that cancer stem cells in multiple myeloma share properties with normal stem cells and exhibit resistance to chemotherapy. These cells contain high levels of enzymes that neutralize toxins, making them harder to treat.
Results from two Phase I trials demonstrate clinical activity of ZOLINZA (vorinostat) combined with bortezomib in patients with relapsed and/or refractory multiple myeloma. The combination treatment showed partial or minimal responses in 48% of evaluable patients, suggesting potential for further evaluation in randomized clinical trials.
Scientists have developed a retinal flow cytometer that allows for continuous monitoring of circulating cells in a mouse's bloodstream. This technology holds promise for treating multiple myeloma by enabling the testing of chemotherapy agents and treatment strategies.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
The study found that lenalidomide-dexamethasone combination therapy slows multiple myeloma disease progression and improves overall survival for patients. The treatment resulted in a median time to disease progression of 11.1 months compared to 4.7 months in the placebo group.
A study of 447 patients with multiple myeloma found that thalidomide improved overall survival and response rates compared to standard chemotherapy. The MPT regimen was associated with significantly better outcomes, making it a potential new treatment option for elderly patients.
Researchers identified 17 genes linked to high-risk multiple myeloma, which can predict poor prognosis and guide therapy. The activity of these genes could help categorize patients' risk early, enabling personalized treatment plans.
Emory researchers identify Ribosomal S6 kinase 2 (RSK2) as a critical downstream signaling protein effector of FGFR3 in myeloma cells. RSK2 plays a key role in regulating cell cycle and survival, and targeting it with drugs may be effective in treating multiple myeloma.
A recent study published in Cancer Epidemiology, Biomarkers & Prevention found that obesity is a significant risk factor for developing multiple myeloma. The research, which analyzed data from over 100,000 participants, discovered that individuals with a higher Body Mass Index (BMI) were more likely to develop the disease.
Researchers at Mayo Clinic are testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow with no cure. The study aims to exploit the protein CD46 to target and kill cancer cells.
A clinical trial combining bortezomib with Doxil has shown promising results in treating relapsed or refractory multiple myeloma, a type of bone marrow cancer. The combination treatment demonstrated a better response rate compared to standard therapy alone, with a median time to progression of 9.3 months.
Researchers explored a new approach to maintenance therapy in patients with multiple myeloma, using pamidronate alone or in combination with thalidomide. The study found that ongoing treatment significantly improved cancer-free survival and overall survival probability compared to standard care.
The Mayo Clinic team has developed a consensus statement recommending the use of pamidronate over zoledronic acid for starting therapy, and stopping or reducing bisphosphonates after two years for safe management of multiple myeloma. The guidelines aim to minimize adverse reactions while maintaining effective bone disease prevention.
The FDA approves REVLIMID(R) (lenalidomide) for treating patients with multiple myeloma who have received at least one prior therapy. Key findings include a higher risk of hematologic toxicity and thromboembolic events in patients receiving the combination treatment.
The study found that the average time to disease progression was approximately eight months for patients taking dexamethasone alone, while those on the Thal/Dex regimen had an average progression time exceeding 17 months. Researchers also reported more frequent side effects with the combination therapy.
A new combination therapy of melphalan, prednisone, and thalidomide has shown significant clinical benefits in elderly multiple myeloma patients. The study found higher response rates and longer event-free survival compared to the standard treatment alone, while also increasing risks of thrombosis, neurological effects, and infection.
The International study reported a significant improvement in median time-to-disease progression with REVLIMID plus dexamethasone compared to placebo plus dexamethasone. The best response rate, complete response and near complete response rates were also higher with REVLIMID plus dexamethasone.
The study found that Rev/Dex reduced myeloma cancer protein levels by over half in 91% of patients, with manageable side effects and a rapid response time. This oral treatment offers an attractive alternative to traditional intravenous therapies.
A large study comparing thalidomide and traditional chemotherapy in multiple myeloma patients found that thalidomide was more effective, with 76% of patients achieving at least partial remission. The treatment also had fewer side effects, particularly deep vein thrombosis compared to granulocytopenia.
Researchers found significantly higher risks of non-Hodgkin's lymphoma and multiple myeloma among HCV patients in Sweden. The risk increases with the duration of HCV infection, suggesting that long-lasting infection may contribute to cancer development.
Researchers found that a combination of thalidomide and dexamethasone is as effective as standard intravenous chemotherapy in treating newly diagnosed multiple myeloma. A newer analog, CC-5013 (lenalidomide), showed promise with fewer side effects.
Researchers at Mayo Clinic are investigating thalidomide's potential to combat multiple myeloma through various studies. The findings suggest that the risk of progression to the disease persists even after 30 years, emphasizing the need for ongoing clinical trials.
A new study shows that VELCADE (bortezomib) can significantly extend survival and induce important responses in relapsed and refractory multiple myeloma patients. The median overall survival was 17.2 months, with a 14.1-month duration of response and 15.3-month time to disease progression.
Researchers at Mayo Clinic have discovered that thalidomide can effectively delay the progression of early-stage multiple myeloma in some patients. In a phase II clinical trial, approximately 80% of patients remained progression-free after one year and 63% were still free from disease progression after two years.
Researchers found that thalidomide therapy works for approximately one year on average, with benefits not being transient. The study's findings offer significant hope for improved survival rates in multiple myeloma patients, an incurable cancer.
A study of 16 patients with active multiple myeloma found that FDG PET scans accurately identified those at high risk, revealing disease spread outside the bone marrow. The scan also showed promise in identifying new disease sites for patients with relapsing disease, suggesting its potential as a complementary diagnostic tool.
A phase II clinical trial shows the oral combination of thalidomide and dexamethasone reduces tumor size by 50% or more in 64% of newly diagnosed multiple myeloma patients. This treatment alternative offers a promising solution to chemotherapy's side effects, including nausea, vomiting, and hair loss.
A recent study by the Southwest Oncology Group found that long-term treatment with prednisone after initial chemotherapy response significantly prolonged patient survival and delayed disease progression in those with multiple myeloma. Patients receiving higher doses of prednisone lived up to 37 months longer than those on lower doses.
The Mayo Clinic study found that the risk of progression from MGUS to multiple myeloma or related cancers is approximately one percent per year, with larger M-protein levels increasing the risk. Patients with very small protein levels had a 14% progression rate at 20 years, while those with high levels had a 60% progression rate.
A two-step approach combining high-dose chemotherapy and autologous stem-cell rescue with mini-transplantation from a sibling significantly reduces transplant-related complications and increases survival rates for patients with advanced-stage multiple myeloma. The procedure results in mild to moderate treatment-related toxicities and a...
The Mayo Clinic study found that thalidomide can stop or slow the progression of multiple myeloma in patients newly diagnosed with this cancer. Thalidomide was previously used to treat advanced myeloma, but this is the first published report documenting its effectiveness as a first-line treatment for early-stage multiple myeloma.
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.